Antifungal Resistance Mechanisms

Antifungal resistance mechanisms are the molecular strategies by which fungi survive exposure to drugs that should inhibit or kill them. Because the antifungal repertoire is small, the loss of any one class to resistance carries outsized consequences, and a recurring set of mechanisms — altered targets, more target, drug efflux, and adaptive stress responses — recurs across the drug classes.

Definition

Antifungal resistance is the reduced susceptibility of a fungus to an antifungal agent to which it was, or would be expected to be, sensitive; the mechanisms are the molecular and physiological changes — target modification, target overexpression, drug efflux, pathway bypass, and adaptive stress responses — that produce this reduced susceptibility.

Scope

This entry covers the principal categories of antifungal resistance: alteration of the drug target, overexpression of the target, active efflux, bypass and stress-response pathways, and biofilm-associated tolerance, together with the distinction between intrinsic and acquired resistance. It is a reference description of how resistance works, not clinical guidance.

Core questions

• What is the difference between intrinsic and acquired resistance?
• How does a single target mutation reduce drug binding across a class?
• Why do efflux pumps matter especially for the azoles?
• How do stress responses and biofilms produce tolerance distinct from classical resistance?

Key concepts

• Intrinsic versus acquired resistance
• Target alteration (ERG11/CYP51 and FKS mutations)
• Target overexpression
• Efflux-pump up-regulation (ABC and MFS transporters)
• Bypass and compensatory pathways
• Hsp90 and calcineurin stress-response signalling
• Biofilm-associated tolerance
• Multidrug resistance

Mechanisms

Resistance arises through a recurring repertoire of mechanisms catalogued across drug classes by Cowen and colleagues (2014) and by Ghannoum and Rice (1999). Target alteration — point mutations in ERG11/CYP51 for azoles or in the FKS genes for echinocandins — lowers drug binding. Target overexpression raises the amount of enzyme the drug must inhibit. Up-regulation of efflux transporters (ATP-binding-cassette and major-facilitator-superfamily pumps) expels azoles before they act and is a leading cause of azole resistance. Beyond these, fungi can rewire sterol biosynthesis to bypass the blocked step, and stress-response circuitry centred on the chaperone Hsp90 and the phosphatase calcineurin buffers the cell against drug stress, stabilising resistance phenotypes. Biofilms confer an additional, largely non-genetic tolerance. Resistance may be intrinsic to a species or acquired under drug pressure.

Clinical relevance

Knowing the mechanism behind a resistant phenotype informs how susceptibility is tested and interpreted and why certain species are harder to treat. The emergence of multidrug-resistant organisms makes these mechanisms a public-health priority (Perlin et al., 2017). This entry describes how resistance arises and is studied; it is not a basis for selecting therapy in an individual patient.

Epidemiology

Resistance is unevenly distributed across species and drug classes. Azole resistance in Aspergillus fumigatus and Candida species is increasingly reported worldwide, and the emergence of Candida auris — frequently resistant to multiple antifungal classes and capable of healthcare-associated transmission — has sharpened concern about multidrug resistance in fungi (Jeffery-Smith et al., 2018).

History

As antifungal use widened from the 1980s onward, resistance followed each class in turn, and the field moved from describing failing therapy to dissecting its molecular basis. The cross-class synthesis by Ghannoum and Rice (1999) and the later mechanistic review by Cowen and colleagues (2014) mark this shift, and the appearance of multidrug-resistant Candida auris around the 2010s reframed antifungal resistance as an emerging global threat.

Debates

How should resistance be distinguished from tolerance in fungi?

Classical resistance reflects a stable rise in the inhibitory concentration, whereas tolerance lets a subpopulation survive above that concentration without a true MIC change; separating the two, and judging their clinical weight, is an active methodological question.

Key figures

• Leah Cowen
• Dominique Sanglard
• David Perlin
• P. David Rogers
• Mahmoud Ghannoum

Seminal works

• ghannoum-rice-1999
• cowen-2014

Frequently asked questions

What is the difference between intrinsic and acquired antifungal resistance?

Intrinsic resistance is a natural property of a species that makes it insusceptible to a drug from the outset, regardless of prior exposure. Acquired resistance develops in a previously susceptible organism through genetic change selected under drug pressure.

Why are efflux pumps so important in azole resistance?

Efflux pumps actively transport the drug out of the fungal cell before it can reach its target enzyme. Up-regulating these ABC and major-facilitator-superfamily transporters lowers the intracellular drug concentration and is one of the most common ways fungi become resistant to azoles.